RAS突变在EML4-ALK阳性肺癌联合治疗中的作用
RAS Mutation Underlies a Rational Polytherapy Strategy in EML4-ALK-Positive Lung Cancer
摘要
·研究一：驱动基因的陆续发现，提示人类肿瘤的发生与环境暴露有关。·研究二：体外实验表明RAS—MAPK通道的活化与ALK抑制剂耐药相关；合理的联合靶向治疗可能对EML4-ALK融合阳性肺癌获得性耐药有抵抗作用。
出处
《循证医学》
CSCD
2016年第1期36-40,共5页
The Journal of Evidence-Based Medicine
参考文献10
-
1Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus Docetaxel for KRAS- mutant advanced non- small- cell lung cancer: A randomised, multicentre, placebo - controlled, phase 2 study[J ]. Lancet Oncol, 2013, 14( 1 ) :38-47.
-
2Chen Z, Cbeng K, Walton Z, et al. A routine lung cancer co- clinical trial identifies genetic modifiers of therapeutic response [J]. Nature, 2012, 483(7391) :613-617.
-
3Day CP, Merlino G, van Dyke T. Preclinical mouse cancer models: A maze of opportunities and challenges [J]. Cell, 2015, 163(1):39-53.
-
4Miller MS, Miller LD. RAS mutations and oncogenesis: Not all RAS mutations are created equally[J]. Front Genet, 2011, 2: 100.
-
5AI- Mulla F, Mackenzie EM. Differences in in vitro invasive capacity induced by differences in Ki- Ras protein mutations [J]. J Pathol, 2001,195(5) :549-556.
-
6Fang S, Wang Z. EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer[J]. Drug Des Devel Ther, 2014, 8: 1595-1611.
-
7Wang H, Huang J, Yu X, et al. Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR- mutated advanced non- small cell lung cancer: A meta-analysis [J]. J Cancer Res Clin Oncol, 2014, 140( 11 ) : 1901-1909.
-
8Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours : Learning from lung cancer [ J ]. Nat Rev Clin Oncol, 2014, 11(8) :473-481.
-
9Tanizaki J, Okamoto I, Takezawa K, et al. Combined effect of ALK and MEK inhibitors in EMIA-ALK-positive non-small- cell lung cancer cells [J]. Br J Cancer, 2012, 106 (4) : 763- 767.
-
10Crystal AS, Shaw AT, Sequist LV, et al. Patient- derived models of acquired resistance can identify effective drug combinations for cancer [J]. Science, 2014, 346 (6216) : 1480-1486.
-
1姚云峰,王宝成.ALK阳性非小细胞肺癌的治疗进展[J].肿瘤学杂志,2015,21(8):651-655.
-
2产翠翠,田静,金艺凤.非小细胞肺癌靶向治疗药物的研究进展[J].中国临床药理学与治疗学,2016,21(3):354-360. 被引量：19
-
3宗立国,陈余清,赵成岭.非小细胞肺癌靶向治疗的一个新趋势：EML4-ALK融合基因[J].国际呼吸杂志,2011,31(21):1671-1676.
-
4胡萍,张运剑.间变性淋巴瘤激酶融合基因阳性的非小细胞肺癌的治疗进展[J].中国全科医学,2017,20(2):232-236. 被引量：1
-
5乔玉环,牛倩,郭瑞霞,刘红彦,黄珊珊,和丽敏.子宫内膜癌组织中P-ERK的表达及意义[J].山东医药,2009,49(2):18-20. 被引量：1
-
6叶绿,杨开选,吴秀丽,黄芹,何英,杨帆,徐炼,宋波,孙亮,喻言.女性生殖系统横纹肌肉瘤中C-myc和ERK1表达特征及相关性的初步探讨[J].现代预防医学,2007,34(13):2435-2437.
-
7尚振川,孙秉中,冯琦,王玮,王莎,张涛,陈志南,王晶.PD98059对慢性髓细胞白血病Ras-MAPK信号转导的作用[J].细胞与分子免疫学杂志,2003,19(1):54-55. 被引量：4
-
8孟宇宏,吴惠.ALK与ALK阳性肿瘤的病理诊断与治疗进展[J].诊断病理学杂志,2014,21(6):361-366. 被引量：3
-
9赵明,宋勇.EML4-ALK在非小细胞肺癌中的研究进展[J].医学研究生学报,2012,25(2):200-203. 被引量：9
-
10邱惠芳,杨文君.间变性淋巴瘤激酶阳性弥漫大B细胞淋巴瘤的研究进展[J].肿瘤学杂志,2016,0(1):65-69. 被引量：2
